MISLEADING MARKETING TACTICS

May 22, 2014

Risperdal has been used for years in the treatment of schizophrenia, bi-polar mania, and irritability associated with autistic disorder in children and adolescents.  In addition, Clinical studies involving small numbers of patients have shown some benefit in using Risperidone for stuttering and Tourette’s syndrome though these are non FDA-approved uses. Another non-FDA approved use of risperidone is for obsessive-compulsive disorders.

Unfortunately, over the years there have been numerous complaints and claims filed regarding the diverse side effects of the drug. These severe side effects include hyperglycemia and diabetes sometimes leading to death. Another unpleasant side effect would be the development of breasts in young men taking Risperdal.

September 11, 2003 the FDA notified Janssen Pharmaceutica, Inc. (through Johnson & Johnson Pharmaceutical Research & Development, L.L.C.) of the new warning requirement. On November 6, 2003, Janssen submitted supplemental NDAs covering an addition of the information to the Warnings section of the PI for Risperdal. However, instead of notifying doctors and patients in a letter of the additional warning added to the label, they omitted that important material information. This letter minimized the risks and was misleading. The read as follows:

 

“Hyperglycemia-related adverse events have infrequently been reported in patients

receiving RISPERDAL. Although confirmatory research is still needed, a body of

evidence from published peer-reviewed epidemiology research suggests that

RISPERDAL is not associated with an increased risk of diabetes when compared to

untreated patients or patients treated with conventional antipsychotics. Evidence also

suggests that RISPERDAL is associated with a lower risk of diabetes than some other

studied atypical antipsychotics.”

In conclusion it is obvious that Janssen intentionally put consumers at risk and as a result these consumers have suffered. Recently the pharmaceutical company has lost several class action law suits because of their deceptive marketing tactics.

Further questions can be directed to the Fears | Nachawati Law Firm by emailing the lead personal injury lawyer, Majed Nachawati at mn@fnlawfirm.com, or by calling our office at 1.866.705.7584.

More Blog Posts

CONTACT US

Use the form below to send us a note, call us at 214.890.0711 or chat with us live. We are eager to help with all your legal needs. Please keep in mind that any unsolicited information sent through our website cannot be treated as confidential. Contacting us through this site does not create a representation relationship with Fears | Nachawati.

Inquiry Type

  • General
  • Personal Injury
  • Immigration
  • Bankruptcy
  • Drug Litigation
  • Family Law

Locations

With offices in Texas, Florida and Colorado and attorneys licensed in Texas, Florida, Colorado, Arkansas and Oklahoma, Fears | Nachawati is dedicated to attaining the best possible solutions for our clients’ business and personal needs. We strive to be professionals who are creative, empathetic and reliable.

All Areas Served

We Can Help

Contact Fears Nachawati today

Free Consulation

Live Chat (Online Now)